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Full coverage for preventive 
medications after myocardial 
infarction
Choudhry et al., N Engl J Med 2011; 365: 2088–2097; doi:10.1056/
NEJMsa1107913
Health-care providers to patients with end-stage renal disease 
(ESRD) are under increasing financial pressure to be as cost 
effective as possible with respect to the choice of medications. 
Factors affecting medication adherence are not well defined 
in the ESRD population, so evaluation of the literature on 
patients with normal kidney function may provide insight. 
Choudhry et al. performed the Post-Myocardial Infarction 
Free Rx Event and Economic Evaluation (MI FREEE) trial 
to assess the impact of oral-medication copayments on out-
comes following myocardial infarction (MI). Patients receiving 
medical and prescription drug benefits through Aetna who 
were discharged from the hospital with the diagnosis code 410 
(the ICD-9 code for MI) were eligible for inclusion. Patients 
agreeing to participate were randomized either to have their 
copayments and coinsurance waived for statins, beta-block-
ers, angiotensin-converting enzyme inhibitors, or angiotensin 
receptor blockers (the full-coverage group) or to maintain their 
current level of copay. Medication adherence was assessed by 
the ratio between the number of days a patient had a supply 
of each medication and the number of days of eligibility for 
that medication. The primary outcome was a composite of first 
readmission for a major vascular event (MI, unstable angina, 
stroke, or congestive heart failure) or coronary revasculariza-
tion (coronary bypass, stenting, or angioplasty). Of the 6768 
potentially eligible patients, 5855 were enrolled. In general, 
adherence to medications was relatively low and quite vari-
able in both arms. Absolute adherence to the three classes of 
medications was 43.9% in the full-coverage group and 38.9% 
in the usual-coverage group. Notably, the standard deviation 
for mean adherence was large (33.7% and 32.7%, respectively), 
suggesting considerable variability in the cohort overall. The 
full-coverage group consistently had greater adherence with an 
absolute difference of 5.4% greater adherence (an improvement 
of 41% in the relative adherence). Although the time to first 
occurrence of the end point was no different between arms, the 
total number of events was lower in the full-coverage group 
(hazard ratio, 0.89). This improvement was driven primarily 
by significant reductions in MI or unstable angina, and stroke 
with congestive heart failure and cardiovascular death had 
non-significant trends in the same direction.
This trial demonstrates that the copay may represent an obsta-
cle to adherence that significantly influences outcomes. Since 
payment for dialysis may include oral medications, extrapolation 
of these findings to people with ESRD suggests the possibility 
that similar improvement in compliance and outcomes may be 
on the horizon.
Lynda Szczech
A pH-sensing receptor  
to excrete bicarbonate
Deyev et al., Cell Metab 2011; 13: 679–689; doi:10.1016/j.cmet.2011.03.022
Although the overall responses of an organism to acid or alkali 
loads are fairly well understood, it remains unclear how cells sense 
changes in pH. In a recent communication, Deyev et al. reported 
that the insulin receptor-related receptor (IRR) is an extracellular 
alkali sensor that is critical for the collecting duct response to alkali. 
IRR is a member of a family of three structurally related recep-
tor tyrosine kinases that includes insulin receptor and insulin-like 
growth factor receptor. The natural agonists of the latter two are 
insulin and the two insulin-like growth factors, I and II. None 
of these ligands activates IRR, and the physiological role of this 
receptor has remained unknown despite multiple efforts seeking 
its ligand. Interestingly, IRR is expressed primarily in the kidneys, 
stomach, and pancreas—organs that have acid- or base-transport-
ing epithelia. However, no overt phenotype was detected in mice 
with targeted inactivation of the IRR gene. Deyev et al. embarked 
on a search for the endogenous agonist of IRR and found that its 
activation could be achieved by an increase in extracellular pH. 
Remarkably, IRR activation by alkaline media was specific, dose 
dependent, reversible, determined by the receptor ectodomain, 
and accompanied by a conformational change of the receptor 
molecule, thus resembling typical features of the ligand–receptor 
interaction. Further, IRR activation triggered intracellular signal-
ing that involved insulin receptor substrate-1 and AKT/PKB as 
well as actin cytoskeleton remodeling. Detailed analysis of IRR−/− 
mice revealed an impaired renal response to alkali loading; the 
urinary excretion of bicarbonate was decreased, and the animals 
developed metabolic alkalosis (Figure). Immunoblot analysis of 
pendrin and of the b1 subunit of the V-H+-ATPase in the kidney 
cortex of alkali-loaded IRR−/− and wild-type mice showed that 
despite the metabolic alkalosis, IRR−/− mice had an approximately 
40% decrease in the abundance of both proteins, indicating that 
Top: Blood pH and bicarbonate in IRR+/+ and IRR−/− mice before and after 
7 days of alkali load administered as 0.28 M solution of NaHCO3 in the 
drinking water. Bottom: Initial urinary bicarbonate excretion and urine pH 
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the absence of IRR disrupted the b-intercalated cells of the col-
lecting duct and thereby prevented the tubule’s ability to secrete 
bicarbonate. The study thus shows that IRR acts as a cell-surface 
alkali-sensing receptor that is involved in the renal adaptation to 
metabolic alkalosis.
Qais Al-Awqati
Calcineurin inhibitors  
induce hypertension by  
activating the renal sodium 
chloride cotransporter
Hoorn et al., Nat Med 2011; 17: 1304–1309; doi:10.1038/nm.2497
Calcineurin inhibitors (CNIs) are immunosuppressive drugs that 
revolutionized the practice of organ transplantation. In addi-
tion to their use in preventing rejection of transplanted organs, 
they are also used now to treat autoimmune disease. Excepting 
nephro toxicity, the most consistent side effect of therapy with CNI 
is hypertension, a considerable problem in patients with already 
significant cardiovascular burden. Interestingly, other side effects 
of CNI are hyperkalemia, hypercalciuria, and, occasionally, meta-
bolic acidosis. This combination resembles some cases of familial 
hyperkalemic hypertension (Gordon’s syndrome), a genetic dis-
order characterized by overactivity of the renal sodium chloride 
cotransporter (NCC) and caused by mutations in genes encod-
ing WNK (with no lysine) kinases. Hoorn et al. postulated that 
CNIs induce hypertension by activating NCC. They found that 
in wild-type mice, tacrolimus caused salt-sensitive hypertension 
and increased the abundance of phosphorylated NCC and the 
NCC-regulatory kinases WNK3, WNK4, and SPAK. The func-
tional importance of NCC in this response was demonstrated by 
the finding that tacrolimus did not affect blood pressure in NCC 
knockout mice (Figure), whereas it caused worse hypertension 
in mice over expressing NCC. Moreover, hydrochlorothiazide, an 
NCC-blocking drug, reversed tacrolimus-induced hypertension. 
Interestingly, in human studies the authors found that kidney 
transplant recipients treated with tacrolimus had a greater frac-
tional chloride excretion in response to bendroflumethiazide, 
another diuretic that is an NCC blocker, than people not treated 
with tacrolimus; more over, in kidney biopsies of patients receiv-
ing CNIs, they found a pronounced increase in NCC and 
phosphorylated-NCC staining compared with controls. In the 
aggregate, these results indicate that CNI-induced chronic hyper-
tension is mediated largely by NCC activation and suggest that the 
best therapy for these patients’ hypertension is thiazide diuretics.
Juan Oliver
Loss of function in DNASE1L3 
causes a familial form of SLE with 
high frequency of nephritis
Al-Mayouf et al., Nat Genet 2011; 43: 1186–1188; doi:10.1038/ng.975
In combination with environmental factors, genetic determinants 
have been shown to have an important role in the pathogenesis 
of systemic lupus erythematosus (SLE), but their exact nature 
remains poorly understood. In genome-wide association studies 
and case-control studies using candidate-gene approaches, several 
risk alleles have recently been identified, and it has been estimated 
that less than 15% of the heritability of SLE can be explained by 
known genetic variants. It is likely that the inability to determine 
much of the heritability of SLE reflects, in part, genetic hetero-
geneity, as well as researchers’ limited ability to ‘bin’ SLE cases 
into subgroups that are more homogeneous in their molecular 
pathology. In an extreme form, this homogeneity would consist 
of a single genetic etiology that acts in a Mendelian fashion. Al-
Mayouf and colleagues postulated that there could be a Mendelian 
phenocopy for SLE, such that a specific genetic etiology could 
be identified and investigated in the common form of SLE, thus 
allowing identification of a subgroup in whom variants of this 
gene contribute to overall risk. The remarkably high rate of con-
sanguinity in the Arab population made it theoretically probable 
that at least one autosomal recessive phenocopy of SLE could 
be identified. In order to enhance their chances of success, the 
authors screened a cohort with SLE for those with a family his-
tory consistent with an autosomal recessive pattern of inheritance; 
they enrolled only subjects with at least two affected siblings and 
healthy consanguineous parents. Seven such families were iden-
tified and studied. In six families, they found a linkage locus on 
3p14.3 with a logarithm of odds (LOD) score of 6.6. This interval 
contained 206 genes. Among these genes, DNASE1L3 was con-
sidered a prime candidate, because SLE pathogenesis is related 
to a decrease in the ability to clear DNA released from apoptotic 
cells, and Dnase1-null mice recapitulate the human disease. The 
protein encoded by DNASE1L3 is one of three human homologs 
of DNase I that cleaves both single- and double-stranded DNA. 
Sequencing of DNASE1L3 uncovered a homozygous 1-bp dele-
tion in DNASE1L3 that segregated perfectly with the disease in a 
strictly Mendelian, fully penetrant, and autosomal recessive fash-
ion in all six families. Additional work provided strong evidence 
that the mutation is pathogenic, and it was not identified in a 
panel of 192 control subjects. The DNASE1L3-related SLE always 
started in childhood and correlated with a high frequency of lupus 
nephritis. This study adds strong confirmation to the critical role 
of impaired clearance of degraded DNA in SLE pathogenesis.
Juan Oliver
(a) Effects of tacrolimus on systolic blood pressure (SBP) of NCC 
knockout mice. (b) Effect of treatment with hydrochlorothiazide (HCTZ) 
or vehicle (Veh) on established tacrolimus (Tac)-induced hypertension 
in wild-type mice.
H
oo
rn
 e
t a
l./
N
at
 M
ed
